Vir Biotechnology, Inc. (VIR)
12.21
+1.19
(+10.80%)
USD |
NASDAQ |
Nov 06, 16:00
12.30
+0.09
(+0.74%)
After-Hours: 20:00
Vir Biotechnology Research and Development Expense (Quarterly) : 78.63M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 78.63M |
| June 30, 2026 | 131.35M |
| March 31, 2026 | 107.00M |
| December 31, 2025 | 85.53M |
| September 30, 2025 | 147.90M |
| June 30, 2025 | 84.61M |
| March 31, 2025 | 114.75M |
| December 31, 2024 | 81.66M |
| September 30, 2024 | 189.71M |
| June 30, 2024 | 97.86M |
| March 31, 2024 | 93.96M |
| December 31, 2023 | 89.54M |
| September 30, 2023 | 143.67M |
| June 30, 2023 | 167.11M |
| March 31, 2023 | 129.40M |
| December 31, 2022 | 153.22M |
| September 30, 2022 | 112.48M |
| Date | Value |
|---|---|
| June 30, 2022 | 113.49M |
| March 31, 2022 | 88.68M |
| December 31, 2021 | 126.82M |
| September 30, 2021 | 96.56M |
| June 30, 2021 | 85.49M |
| March 31, 2021 | 133.47M |
| December 31, 2020 | 85.76M |
| September 30, 2020 | 68.45M |
| June 30, 2020 | 77.42M |
| March 31, 2020 | 57.16M |
| December 31, 2019 | 48.11M |
| September 30, 2019 | 38.19M |
| June 30, 2019 | 28.70M |
| March 31, 2019 | 24.83M |
| December 31, 2018 | 21.08M |
| September 30, 2018 | 29.13M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 515.00M |
| Vaxcyte, Inc. | 270.33M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |